Los Angeles, October 15, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient has been treated with TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK). Trethera’s multi-site Phase 1 study will evaluate TRE-515 monotherapy in up […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-10-14 23:44:052021-10-19 05:22:39Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515
Los Angeles, May 25, 2021—Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancers and autoimmune diseases, is pleased to announce the appointment of renowned autoimmunity researcher Dr. Larry Steinman to its Scientific Advisory Board. Dr. Steinman will be advising Trethera regarding TRE-515 development, a […]
Los Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies. Trethera will […]
Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-03-16 16:50:462021-03-16 16:52:33Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-02-24 03:50:002021-03-08 18:05:11Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515
/in News /by Trethera SupportLos Angeles, October 15, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient has been treated with TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK). Trethera’s multi-site Phase 1 study will evaluate TRE-515 monotherapy in up […]
Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board
/in News /by Trethera SupportLos Angeles, May 25, 2021—Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancers and autoimmune diseases, is pleased to announce the appointment of renowned autoimmunity researcher Dr. Larry Steinman to its Scientific Advisory Board. Dr. Steinman will be advising Trethera regarding TRE-515 development, a […]
Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy
/in News /by Trethera SupportLos Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies. Trethera will […]
Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
/in News /by Trethera SupportLos Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]
Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
/in News /by Trethera SupportLos Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]